Recent real-world treatment patterns and outcomes in US patients with relapsed/refractory multiple myeloma-Reference-Cited by-同舟云学术

Recent real-world treatment patterns and outcomes in US patients with relapsed/refractory multiple myeloma

Published:2020-08-26 Issue:9 Volume:13 Page:1017-1025
ISSN:1747-4086
Container-title:Expert Review of Hematology
language:en
Short-container-title:Expert Review of Hematology

Author:

Bruno Amanda S.¹²,Willson Jenny L.³,Opalinska Joanna M.¹,Nelson Jeanenne J.⁴,Lunacsek Orsolya E.⁵,Stafkey-Mailey Dana R.⁵,Willey Joanne P.⁵

Affiliation:

1. Value Evidence and Outcomes, GlaxoSmithKline, Collegeville, PA, USA

2. Real World Evidence Oncology, Bayer HealthCare Pharmaceuticals, Inc, Whippany, NJ, USA

3. Value Evidence and Outcomes, GlaxoSmithKline, London, UK

4. Oncology Epidemiology, GlaxoSmithKline, Research Triangle Park, NC, USA

5. Global Health Economics and Outcomes Research, Xcenda, Palm Harbor, FL, USA

Funder

GlaxoSmithKline

Publisher

Informa UK Limited

Subject

Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/17474086.2020.1800451

Reference30 articles.

1. Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

2. Progress and Paradigms in Multiple Myeloma

3. Surveillance Epidemiology and End Results (SEER). SEER cancer stat facts: myeloma 2018 [cited 2018 Aug 23]. Available from: http://seer.cancer.gov/statfacts/html/mulmy.html

4. National Comprehensive Cancer Network (NCCN) NCCN clinical practice guidelines in oncology. Multiple Myeloma. Version 2. 2019;2018. Available from: https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf

5. Treatment of relapsed and refractory multiple myeloma

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of ibrutinib dose adjustment on TTNT in first-line CLL/SLL: a real-world analysis using target trial emulation;Blood Neoplasia;2024-09

2. Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma;American Journal of Hematology;2024-06-10

3. Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial;Nature Medicine;2024-06-03

4. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma;New England Journal of Medicine;2024-06-03

5. Comparative effectiveness of lenalidomide/dexamethasone-based triplet regimens for treatment of relapsed and/or refractory multiple myeloma in the United States: An analysis of real-world electronic health records data;Current Problems in Cancer;2024-06